Form 4: Metagenomi CFO Sells Shares for Tax Withholding

Metagenomi Therapeutics, Inc. reports that Chief Financial Officer Pamela Wapnick sold 2,884 shares of common stock on June 5, 2026, to cover tax withholding obligations upon the vesting of restricted stock units.

Summary

• Pamela Wapnick, Chief Financial Officer of Metagenomi Therapeutics, Inc., sold 2,884 shares of common stock on June 5, 2026.
• The sale was executed at a price of $1.299 per share.
• These shares were automatically sold to satisfy the reporting person's tax withholding obligations related to the vesting of restricted stock units granted on April 1, 2024, and April 1, 2025.
• This transaction does not represent a volitional trade by the reporting person.
• Following the transaction, Ms. Wapnick beneficially owns 208,491 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The sale is purely for tax withholding purposes related to RSU vesting and is not a discretionary sale, thus not reflecting negative sentiment from management.

Positives

• The sale was an automatic transaction to cover tax obligations, not a discretionary sale, indicating no negative sentiment from management regarding the company's stock.
• The reporting person continues to beneficially own a significant number of shares (208,491) directly.

Negatives

• A portion of the reporting person's holdings was sold, reducing their direct ownership, albeit for tax purposes.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports a past transaction.

Management Comments

• The sale was automatically executed for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units.
• This transaction does not represent a volitional trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The nature of this specific transaction, a sale to cover tax obligations upon vesting of RSUs, is common and generally viewed neutrally by the market, as it is not indicative of a change in the insider's fundamental view of the company's prospects.

Stakeholder Impact

• Shareholders: The transaction is unlikely to have a significant impact on the share price as it is a routine tax-related event and not a reflection of management's view on the company's future performance. The reporting person retains a substantial number of shares.

Key Dates

Keywords

Form 4, SEC Filing, Metagenomi Therapeutics, MGX, Pamela Wapnick, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership